Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline

Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984

Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol.

Stocker, R., Bowry, V. W., & Frei, B. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.5.1646 · Cited by 797

Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation

Mohr, D., Bowry, V. W., & Stocker, R. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90237-p · Cited by 313

Biomedical and clinical aspects of coenzyme Q

Littarru, G. P. (1993) · Journal of Molecular Medicine · doi:10.1007/bf00184478 · Cited by 310

Electron Transport-Linked Ubiquinone-Dependent Recycling of α-Tocopherol Inhibits Autooxidation of Mitochondrial Membranes

Lass, A., & Sohal, R. S. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0606 · Cited by 162

Effect of coenzyme Q 10 and α‐tocopherol content of mitochondria on the production of superoxide anion radicals

Lass, A., & Sohal, R. S. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.1.87 · Cited by 128

Bioavailability of four oral Coenzyme Q10 formulations in healthy volunteers

Weis, M., Mortensen, S. A., Rassing, M. R., Sonnergaard, J. M., Poulsen, G., & Rasmussen, S. N. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90038-8 · Cited by 102

Antioxidative activity of ubiquinol-10 at physiologic concentrations in human low density lipoprotein

Kontush, A., Hübner, C., Finckh, B., Kohlschütter, A., & Beisiegel†, U. (1995) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00115-s · Cited by 75

Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man.

Tomono, Y., Hasegawa, J., Seki, T., Motegi, K., & Morishita, N. (1986) · PubMed · Cited by 73

Interactions between ubiquinones and vitamins in membranes and cells

Constantinescu, A., Maguire, J. J., & Packer, L. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90013-2 · Cited by 73

Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations

Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173

Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target

Barber, S. C., & Shaw, P. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.018 · Cited by 647

Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics

Bhagavan, H. N., & Chopra, R. K. (2006) · Free Radical Research · doi:10.1080/10715760600617843 · Cited by 550

Mitochondrial Diseases of the Brain

Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 426

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 410

A modern approach to the treatment of mitochondrial disease

The Mitochondrial Medicine Society, Parikh, S., Saneto, R. P., Falk, M. J., Anselm, I. A., Cohen, B. H., & Haas, R. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0046-0 · Cited by 349

Mitochondrial Approaches for Neuroprotection

Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294

Energy metabolism in ALS: an underappreciated opportunity?

Vandoorne, T., Bock, K. D., & Bosch, L. V. D. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1835-x · Cited by 260

Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations

Bhagavan, H. N., & Chopra, R. K. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.003 · Cited by 243

Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges

Arenas‐Jal, M., Suñé‐Negre, J. M., & García‐Montoya, E. (2020) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12539 · Cited by 239

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III

Kaufmann, P., Thompson, J. L. P., Levy, G., Buchsbaum, R., Shefner, J. M., Krivickas, L. S., Katz, J., Rollins, Y. D., Barohn, R. J., Jackson, C. E., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21743 · Cited by 236

α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease

Halliday, G. M., Ophof, A., Broe, M., Jensen, P. H., Kettle, E., Fedorow, H., Cartwright, M., Carew‐Jones, F., Shepherd, C. E., & Double, K. L. (2005) · Brain · doi:10.1093/brain/awh584 · Cited by 224

A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease

The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 220

Targeting the Redox Balance in Inflammatory Skin Conditions

Wagener, F. A. D. T. G., Carels, C. E. L., & Lundvig, D. M. S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14059126 · Cited by 223

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

Storch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205

The emerging role of nutrition in Parkinson's disease

Seidl, S. E., Santiago, J. A., Bilyk, H. T., & Potashkin, J. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00036 · Cited by 218

Coenzyme Q10 Deficiency and Response to Supplementation in Pediatric and Adolescent Migraine

Hershey, A. D., Powers, S. W., Vockell, A.-L. B., LeCates, S. L., Ellinor, P. L., Segers, A. M., Burdine, D., Manning, P., & Kabbouche, M. A. (2007) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2007.00652.x · Cited by 197

Coenzyme Q10 effects in neurodegenerative disease

Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 189

Safety assessment of coenzyme Q 10 (CoQ 10 )

Hidaka, T., Fujii, K., Funahashi, I., Fukutomi, N., & Hosoe, K. (2008) · BioFactors · doi:10.1002/biof.5520320124 · Cited by 187

Clinical applications of coenzyme Q₁₀

Garrido-Maraver, J. (2014) · Frontiers in Bioscience · doi:10.2741/4231 · Cited by 178

Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants

Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 169

The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathies

Tarnopolsky, M. A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.05.001 · Cited by 161

Tolerance of high‐dose (3,000 mg/day) coenzyme Q10 in ALS

Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M. F., Traynor, B., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187070.35365.d7 · Cited by 154

Coenzyme Q10 Therapy

Garrido‐Maraver, J., Cordero, M. D., Oropesa-Ávila, M., Fernández-Vega, A., de la Mata, M., Pavón, A. D., de Miguel, M., Calero, C. P., Paz, M. V., Cotán, D., et al. (2014) · Molecular Syndromology · doi:10.1159/000360101 · Cited by 161

Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease

Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, M. F., & Lu, B. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-109 · Cited by 151

Coenzyme Q10 and Heart Failure

Sharma, A., Fonarow, G. C., Butler, J., Ezekowitz, J. A., & Felker, G. M. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002639 · Cited by 150

Retinal Damage Caused by High Intraocular Pressure–Induced Transient Ischemia is Prevented by Coenzyme Q10 in Rat

Nucci, C., Tartaglione, R., Cerulli, A., Mancino, R., Spanò, A., Cavaliere, F., Rombolà, L., Bagetta, G., Corasaniti, M. T., & Morrone, L. A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82022-8 · Cited by 143

Mitochondrial mechanisms of estrogen neuroprotection.

Simpkins, J., & Dykens, J. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.04.007 · Cited by 7

The Promise of Neuroprotective Agents in Parkinson?s Disease

Seidl, S. E., & Potashkin, J. A. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00068 · Cited by 145

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases

Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139

A randomized trial of coenzyme Q 10 in mitochondrial disorders

Glover, E. I., Martin, J. C., Maher, A. C., Thornhill, R. E., Moran, G. R., & Tarnopolsky, M. A. (2010) · Muscle & Nerve · doi:10.1002/mus.21758 · Cited by 137

Mitochondrial targeting of quinones: Therapeutic implications

Cochemé, H. M., Kelso, G. F., James, A. M., Ross, M. F., Trnka, J., Mahendiran, T., Asin-Cayuela, J., Blaikie, F. H., Manas, A. B., Porteous, C. M., et al. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.02.007 · Cited by 138

Therapeutic use of coenzyme Q 10 and coenzyme Q 10 -related compounds and formulations

Villalba, J. M., Parrado‐Fernández, C., González, M. S., & Alcain, F. J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003727495 · Cited by 139

Study on safety and bioavailability of ubiquinol (Kaneka QH™) after single and 4-week multiple oral administration to healthy volunteers

Hosoe, K., Kitano, M., Kishida, H., Kubo, H., Fujii, K., & Kitahara, M. (2006) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2006.07.001 · Cited by 133

A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways

Tsai, K., Huang, Y., Kao, C.-L., Yang, D., Lee, H., Chou, H., Chen, Y., Chiou, G., Chen, L.-H., Yang, Y.-P., et al. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.01.011 · Cited by 133

Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease

Hickey, M. A., Zhu, C., Medvedeva, V. P., Lerner, R. P., Patassini, S., Franich, N. R., Maiti, P., Frautschy, S. A., Zeitlin, S. O., Levine, M. S., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-12 · Cited by 135

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127

The uptake and distribution of coenzyme Q(10)

Miles, M. V. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.02.012 · Cited by 126

A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine

Slater, S. K., Nelson, T. D., Kabbouche, M. A., LeCates, S. L., Horn, P. S., Segers, A. M., Manning, P., Powers, S. W., & Hershey, A. D. (2011) · Cephalalgia · doi:10.1177/0333102411406755 · Cited by 125

Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation

Potgieter, M., Pretorius, E., & Pepper, M. S. (2013) · Nutrition Reviews · doi:10.1111/nure.12011 · Cited by 124

An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition

Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124

Treatment of mitochondrial electron transport chain disorders: A review of clinical trials over the past decade

Kerr, D. S. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.11.005 · Cited by 121

Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications☆

Bolaños, J. P., Moro, M. Á., Lizasoaín, I., & Almeida, Á. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.009 · Cited by 120

Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: Neuroprotection and amelioration of symptoms by water-soluble formulation of Coenzyme Q10

Somayajulu‐Nitu, M., Sandhu, J. K., Cohen, J. S., Sikorska, M., Sridhar, T., Matei, A., Borowy‐Borowski, H., & Pandey, S. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-88 · Cited by 117

Risk assessment for coenzyme Q10 (Ubiquinone)

Hathcock, J. N., & Shao, A. (2006) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2006.05.006 · Cited by 114

Coenzyme Q10 deficiency in patients with Parkinson's disease

Mischley, L. K., Allen, J., & Bradley, R. D. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.03.023 · Cited by 111

Coenzyme Q10 prevents high glucose-induced oxidative stress in human umbilical vein endothelial cells

Tsuneki, H., Sekizaki, N., Suzuki, T., Kobayashi, S., Wada, T., Okamoto, T., Kimura, I., & Sasaoka, T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.03.006 · Cited by 104

Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease

Beal, M. F. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70812-0 · Cited by 104

Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management.

Kidd, P. M. (2005) · PubMed · Cited by 104

Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status

Öz, G., Hutter, D., Tkáč, I., Clark, H. B., Gross, M. D., Jiang, H., Eberly, L. E., Bushara, K. O., & Gomez, C. M. (2010) · Movement Disorders · doi:10.1002/mds.23067 · Cited by 104

Coenzyme Q10:A Review of Its Promise as a Neuroprotectant

Young, A. J., Johnson, S., Steffens, D. C., & Doraiswamy, P. M. (2007) · CNS Spectrums · doi:10.1017/s1092852900020538 · Cited by 100

Review of clinical trials for mitochondrial disorders: 1997-2012

Kerr, D. S. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0176-7 · Cited by 96

Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications

Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96

The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease

Haas, R. H. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.008 · Cited by 92

Coenzyme Q10 suppresses oxLDL‐induced endothelial oxidative injuries by the modulation of LOX‐1‐mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway

Tsai, K., Chen, L., Chiou, S., Chiou, G., Chen, Y., Chou, H., Chen, L., Chen, H., Chiu, T., Tsai, C., et al. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100147 · Cited by 94

Co‐enzyme Q10 and idebenone use in Friedreich's ataxia

Parkinson, M. H., Schulz, J. B., & Giunti, P. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12322 · Cited by 92

Clinical aspects of coenzyme Q10: an update

Littarru, G. P., & Tiano, L. (2005) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000171123.60665.16 · Cited by 92

Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects

The Huntington Study Group Pre2CARE Investigators (2010) · Movement Disorders · doi:10.1002/mds.22408 · Cited by 91

Coenzyme Q10: is there a clinical role and a case for measurement?

Molyneux, S. L., Young, J. M., Florkowski, C. M., Lever, M., & George, P. M. (2008) · PubMed Central · Cited by 87

Strategies for oral delivery and mitochondrial targeting of CoQ10

Zaki, N. M. (2014) · Drug Delivery · doi:10.3109/10717544.2014.993747 · Cited by 87

Antioxidants, Supplements, and Parkinson's Disease

Weber, C. A., & Ernst, M. E. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g551 · Cited by 85

Neurochemical abnormalities in premanifest and early spinocerebellar ataxias

Joers, J. M., Deelchand, D. K., Lyu, T., Emir, U. E., Hutter, D., Gomez, C. M., Bushara, K. O., Eberly, L. E., & Öz, G. (2018) · Annals of Neurology · doi:10.1002/ana.25212 · Cited by 85

Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases

Testai, L., Martelli, A., Flori, L., Cicero, A. F. G., & Colletti, A. (2021) · Nutrients · doi:10.3390/nu13051697 · Cited by 86

Coenzyme Q10 and Immune Function: An Overview

Mantle, D., Heaton, R. A., & Hargreaves, I. P. (2021) · Antioxidants · doi:10.3390/antiox10050759 · Cited by 85

Treating neurodegeneration by modifying mitochondria: potential solutions to a “complex” problem

Swerdlow, R. H. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1676 · Cited by 81

Mitochondrial medicine for neurodegenerative diseases

Du, H., & Yan, S. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.004 · Cited by 82

Coenzyme Q treatment of neurodegenerative diseases of aging

Galpern, W. R., & Cudkowicz, M. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.01.004 · Cited by 78

Effects of coenzyme Q10supplementation on metabolic profile in diabetes: a systematic review and meta-analysis

Suksomboon, N., Poolsup, N., & Juanak, N. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12280 · Cited by 77

Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism

Abdin, A. A., & Hamouda, H. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.033 · Cited by 77

Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson’s Disease

Sohrabi, T., Mirzaei-Behbahani, B., Zadali, R., Pirhaghi, M., Morozova‐Roche, L. A., & Meratan, A. A. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.167992 · Cited by 79

Therapeutic role of coenzyme Q10 in Parkinson's disease

Shults, C. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.002 · Cited by 81

Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection

Russo, R., Cavaliere, F., Rombolà, L., Gliozzi, M., Cerulli, A., Nucci, C., Fazzi, E. M., Bagetta, G., Corasaniti, M. T., & Morrone, L. A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)01139-4 · Cited by 76

Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development

Nierenberg, A. A., Kansky, C., Brennan, B. P., Shelton, R. C., Perlis, R. H., & Iosifescu, D. V. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412449303 · Cited by 78

A Randomized, Double-Blind, Placebo-Controlled Study of Oral Coenzyme Q10 to Relieve Self-Reported Treatment-Related Fatigue in Newly Diagnosed Patients with Breast Cancer

Lesser, G. J., Case, D., Stark, N. N., Williford, S., Giguere, J. K., Garino, L. A., Naughton, M. J., Vitolins, M. Z., Lively, M. O., & Shaw, E. G. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.03.003 · Cited by 77

Microencapsulation of ubiquinone-10 in carbohydrate matrices for improved stability

Bule, M. V., Singhal, R. S., & Kennedy, J. F. (2010) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2010.07.012 · Cited by 77

Comprehensive Behavioral Testing in the R6/2 Mouse Model of Huntington's Disease Shows No Benefit from CoQ10 or Minocycline

Menalled, L., Patry, M., Ragland, N., Lowden, P. A. S., Goodman, J., Minnich, J., Zahasky, B., Park, L., Leeds, J. M., Howland, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009793 · Cited by 70

Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough

Löhle, M., & Reichmann, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.025 · Cited by 70

Current state of coenzyme Q10 production and its applications

Jeya, M., Moon, H.-J., Lee, J.-L., Kim, I., & Lee, J.-K. (2009) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-009-2380-2 · Cited by 66

Water-soluble formulation of Coenzyme Q10 inhibits Bax-induced destabilization of mitochondria in mammalian cells

Naderi, J., Somayajulu‐Nitu, M., Mukerji, A., Sharda, P. R., Sikorska, M., Borowy‐Borowski, H., Antonsson, B. E., & Pandey, S. (2006) · APOPTOSIS · doi:10.1007/s10495-006-8417-4 · Cited by 66

Solanesol: a review of its resources, derivatives, bioactivities, medicinal applications, and biosynthesis

Yan, N., Liu, Y., Gong, D., Du, Y., Zhang, H., & Zhang, Z. (2015) · Phytochemistry Reviews · doi:10.1007/s11101-015-9393-5 · Cited by 66

CoQ10 in progressive supranuclear palsy

Apetauerova, D., Scala, S., Hamill, R. W., Simon, D. K., Pathak, S., Ruthazer, R., Standaert, D. G., & Yacoubian, T. A. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000266 · Cited by 68

Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease

Liang, Q., Smith, A. D., Pan, S., Tyurin, V. A., Kagan, V. E., Hastings, T. G., & Schor, N. F. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.04.011 · Cited by 65

CoQ10Function and Role in Heart Failure and Ischemic Heart Disease

Ayer, A., Macdonald, P. S., & Stocker, R. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034258 · Cited by 65

Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson’s disease rat model

Park, H. W., Park, C. G., Park, M. J., Lee, S. H., Park, H. R., Lim, J., Paek, S. H., & Choy, Y. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-66493-w · Cited by 67

Clinical trials of coenzyme Q10 in neurological disorders

Shults, C. W., & Haas, R. (2005) · BioFactors · doi:10.1002/biof.5520250113 · Cited by 62

Potential role of coenzyme Q10 in health and disease conditions

Rodick, T. C., Seibels, D. R., Babu, J. R., Huggins, K. W., Ren, G., & Mathews, S. T. (2018) · Nutrition and Dietary Supplements · doi:10.2147/nds.s112119 · Cited by 58

Personalized Medicine in Mitochondrial Health and Disease: Molecular Basis of Therapeutic Approaches Based on Nutritional Supplements and Their Analogs

Tragni, V., Primiano, G., Tummolo, A., Beltrame, L. C., Piana, G. L., Sgobba, M. N., Cavalluzzi, M. M., Paterno, G., Gorgoglione, R., Volpicella, M., et al. (2022) · Molecules · doi:10.3390/molecules27113494 · Cited by 55

Neuroprotection by solanesol against ethidium bromide-induced multiple sclerosis-like neurobehavioral, molecular, and neurochemical alterations in experimental rats

Sharma, N., Upadhayay, S., Shandilya, A., Sahu, R., Singh, A., Rajkhowa, B., & Mehan, S. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100051 · Cited by 54

The Podocyte Power-Plant Disaster and Its Contribution to Glomerulopathy

Müller‐Deile, J., & Schiffer, M. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00209 · Cited by 53

Solanesol: Added value from Solanaceous waste

Taylor, M. A., & Fraser, P. D. (2011) · Phytochemistry · doi:10.1016/j.phytochem.2011.03.015 · Cited by 51

The footprints of mitochondrial impairment and cellular energy crisis in the pathogenesis of xenobiotics-induced nephrotoxicity, serum electrolytes imbalance, and Fanconi’s syndrome: A comprehensive review

Heidari, R. (2019) · Toxicology · doi:10.1016/j.tox.2019.05.002 · Cited by 50

Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases

Sureda, F. X., Junyent, F., Verdaguer, E., Auladell, C., Pelegrí, C., Vilaplana, J., Folch, J., Canudas, A. M., Zárate, C. B., Pallàs, M., et al. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049732 · Cited by 49

A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Coenzyme Q10 Therapy in Hypertensive Patients With the Metabolic Syndrome

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., & George, P. M. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2011.209 · Cited by 59

Mitochondrial dysfunction in mouse trisomy 16 brain

Bambrick, L. L., & Fiskum, G. M. (2007) · Brain Research · doi:10.1016/j.brainres.2007.10.045 · Cited by 51

Prolonged Intake of Coenzyme Q10 Impairs Cognitive Functions in Mice

Sumien, N., Heinrich, K. R., Shetty, R. A., Sohal, R. S., & Forster, M. J. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.110437 · Cited by 46

Ubiquinol‐10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome

Fukuda, S., Nojima, J., Kajimoto, O., Yamaguti, K., Nakatomi, Y., Kuratsune, H., & Watanabe, Y. (2016) · BioFactors · doi:10.1002/biof.1293 · Cited by 50

Three-Year Follow-Up of High-Dose Ubiquinol Supplementation in a Case of Familial Multiple System Atrophy with Compound Heterozygous COQ2 Mutations

Mitsui, J., Koguchi, K., Momose, T., Takahashi, M., Matsukawa, T., Yasuda, T., Tokushige, S., Ishiura, H., Goto, J., Nakazaki, S., et al. (2017) · The Cerebellum · doi:10.1007/s12311-017-0846-9 · Cited by 47

Biological Variation of Coenzyme Q10

Molyneux, S. L., Florkowski, C. M., Lever, M., & George, P. M. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.043653 · Cited by 43

An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial

Prasuhn, J., Brüggemann, N., Heßler, N., Berg, D., Gasser, T., Brockmann, K., Olbrich, D., Ziegler, A., König, I. R., Klein, C., et al. (2019) · Neurological Research and Practice · doi:10.1186/s42466-019-0033-1 · Cited by 42

Clinical trials for neuroprotection in Parkinson??s disease: overcoming angst and futility?

Hung, A. Y., & Schwarzschild, M. A. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32826388d6 · Cited by 42

Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline

Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984

Observation of Coenzyme Q_(10) on the treatment of Parkinson 's disease

Wang, S. (2014) · Hebei Journal of Traditional Chinese Medicine

Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q 10 in parkinsonian patients

Shults, C. W., Beal, M. F., Fontaine, D., Nakano, K., & Haas, R. (1998) · Neurology · doi:10.1212/wnl.50.3.793 · Cited by 116

Does High-Dose Coenzyme Q 10 Improve Oxidative Damage and Clinical Outcomes in Parkinson's Disease?

Seet, R. C. S., Lim, E. C. H., Tan, J. J. H., Quek, A. M. L., Chow, A. W. L., Chong, W.-L., Ng, M. P.-E., Ong, C. N., & Halliwell, B. B. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5801 · Cited by 39

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 410